While there are few silver linings to the cloud created by COVID-19, the pandemic that has killed tens of thousands, hobbled economies worldwide and drove millions to quarantine in their homes, one may be a new appreciation of telemedicine. “If something good could come out of this crisis, it’s that…
News
FFF Enterprises and Bionews announced today that both rare and orphan disease advocates are joining forces to provide patients with resources to help them connect as a community and continue to manage their health during this time when many are finding themselves alone. Recognized as the nation’s leading supplier of…
The American Thoracic Society has published its first official guidelines for how best to detect and diagnosis sarcoidosis in clinical practice. The guidelines were published in the American Journal of Respiratory and Critical Care Medicine, in an article titled “Diagnosis and Detection of Sarcoidosis. An Official American…
The National Organization for Rare Disorders (NORD) has opened a financial assistance program for people in rare disease community who are affected by the COVID-19 pandemic in the U.S. Called the NORD COVID-19 Critical Relief Program, the effort will provide up to $1,000 annually to those eligible to…
Adiponectin, an anti-inflammatory protein produced by adipose tissue, was seen to be elevated in the blood of people with sarcoidosis in a small study, and may help to ease disease severity.  The finding was…
The National Heart, Lung, and Blood Institute, part of the National Institutes of Health (NIH), has given a $1.98 million grant to Wayne State University researchers to refine an antibody-based technology that can help to distinguish people with  sarcoidosis from tuberculosis patients and healthy individuals. Sarcoidosis is an…
First, the bad news: If you’re one of the 30 million or so Americans with a rare disease, you probably have lower immunity to the novel coronavirus than most people. Now, the good news: You already know how to face loneliness and adversity — qualities that make you far stronger…
The Foundation for Sarcoidosis Research is partnering with the American Lung Association for its sixth annual effort to raise awareness about sarcoidosis and provide resources for patients, caregivers, and clinicians during Sarcoidosis Awareness Month in April, and specifically to address concerns in the midst of the…
The Living Rare, Living Stronger Patient and Family Forum, originally set for May 14–16 in Cleveland, Ohio, has been postponed until July 18–20 because of the coronavirus disease COVID-19 pandemic. The event’s sponsor, the National Organization for Rare Disorders (NORD), said it will still take place at the…
Results of a Phase 1b/2a clinical study evaluating ATYR1923 in people with pulmonary sarcoidosis are likely to be delayed due to the COVID-19 pandemic, its developer, aTyr Pharma, announced. ATYR1923 is a first-in-class therapy being developed to possibly different types of interstitial lung diseases (ILDs) — a…
Recent Posts
- We need to keep sharing our stories and reject the ‘sickfluencer’ narrative
- Cell-released proteins may predict sarcoidosis treatment response
- Registry study finds heart sarcoidosis outcomes vary by feature
- Critical conversations: Why talking about our medications is essential
- Study challenges theory of microbes as sarcoidosis cause
- FDA, developer align on protocols for trial of pulmonary sarcoidosis drug
- Large study ties sarcoidosis to risk of permanent liver scarring
- Reflecting with gratitude on what sarcoidosis has brought to my life
- Lingering heart inflammation tied to cardiac sarcoidosis relapse risk
- Study identifies three genes that may influence sarcoidosis risk